HK1022639A1 - New use for 1,3-propanediol derivatives. - Google Patents

New use for 1,3-propanediol derivatives.

Info

Publication number
HK1022639A1
HK1022639A1 HK00101496A HK00101496A HK1022639A1 HK 1022639 A1 HK1022639 A1 HK 1022639A1 HK 00101496 A HK00101496 A HK 00101496A HK 00101496 A HK00101496 A HK 00101496A HK 1022639 A1 HK1022639 A1 HK 1022639A1
Authority
HK
Hong Kong
Prior art keywords
new use
propanediol derivatives
optionally substituted
propanediol
derivatives
Prior art date
Application number
HK00101496A
Other languages
English (en)
Inventor
Sylvain Cottens
Robert Paul Hof
Roland Wenger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1022639A1 publication Critical patent/HK1022639A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Light Receiving Elements (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK00101496A 1996-11-19 2000-03-10 New use for 1,3-propanediol derivatives. HK1022639A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Publications (1)

Publication Number Publication Date
HK1022639A1 true HK1022639A1 (en) 2000-08-18

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101496A HK1022639A1 (en) 1996-11-19 2000-03-10 New use for 1,3-propanediol derivatives.

Country Status (25)

Country Link
US (3) US6274629B1 (pt)
EP (2) EP1312359B1 (pt)
JP (2) JP4004070B2 (pt)
CN (2) CN1293876C (pt)
AT (2) ATE275947T1 (pt)
AU (1) AU728420B2 (pt)
BR (1) BR9713105A (pt)
CA (1) CA2270952C (pt)
CZ (1) CZ174999A3 (pt)
DE (2) DE69738033T2 (pt)
DK (1) DK1312359T3 (pt)
ES (2) ES2227726T3 (pt)
GB (1) GB9624038D0 (pt)
HK (1) HK1022639A1 (pt)
HU (1) HUP0000343A3 (pt)
ID (1) ID21568A (pt)
IL (1) IL129824A (pt)
NO (1) NO992259D0 (pt)
NZ (1) NZ335629A (pt)
PL (1) PL190348B1 (pt)
PT (2) PT1312359E (pt)
RU (1) RU2217136C2 (pt)
SI (1) SI1312359T1 (pt)
SK (1) SK284806B6 (pt)
WO (1) WO1998022100A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69923579T2 (de) 1998-11-11 2006-01-12 Novartis Ag Herstellung von 2-amino-2(2-(4-alkylphenyl)äthyl)propan-1,3-diolen
SK8332002A3 (en) * 1999-12-16 2003-04-01 Teva Pharma Novel processes for making- and a new crystalline form of leflunomide
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
CN100479814C (zh) * 2001-02-22 2009-04-22 诺瓦提斯公司 促淋巴细胞归巢剂在制备用于治疗移植物功能恢复延迟的药物中的用途
CA2444278C (en) * 2001-04-20 2011-11-22 Debiopharm S.A. Modified cyclosporine which can be used as a pro-drug and use thereof
EP1429845B1 (en) * 2001-06-08 2009-03-11 Novartis AG Treatment or prophylaxis of insulin-producing cell graft rejection
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
AU2003202495B2 (en) 2002-01-11 2006-07-20 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
PE20150676A1 (es) 2003-04-08 2015-05-17 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
US7838562B2 (en) * 2003-06-24 2010-11-23 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
US20080096972A1 (en) * 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
PL1961734T3 (pl) 2005-12-15 2012-02-29 Mitsubishi Tanabe Pharma Corp Związek aminowy i jego zastosowanie do celów medycznych
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
KR102255357B1 (ko) * 2013-03-05 2021-05-24 바이오콘 리미티드 2-아미노-1,3-프로판디올 화합물 및 이의 염의 제조방법
US20180250235A1 (en) 2015-09-18 2018-09-06 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
EP4353709A1 (en) * 2021-05-31 2024-04-17 Shanghai Yonsun Biotechnology Co., Ltd. Pharmaceutical salt of fingolimod, preparation method therefor, pharmaceutical composition containing same and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
DK0605442T3 (da) * 1991-07-25 2003-08-04 Idec Pharma Corp Rekombinante antistoffer til human terapi
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
SK282225B6 (sk) * 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
PT990440E (pt) * 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido

Also Published As

Publication number Publication date
US6274629B1 (en) 2001-08-14
DE69730727T2 (de) 2005-09-22
US6486209B2 (en) 2002-11-26
PT1312359E (pt) 2007-11-09
SK284806B6 (sk) 2005-11-03
AU5483198A (en) 1998-06-10
JP2001503780A (ja) 2001-03-21
EP0941082B1 (en) 2004-09-15
SK65999A3 (en) 1999-12-10
EP1312359A3 (en) 2004-01-02
AU728420B2 (en) 2001-01-11
CN1515253A (zh) 2004-07-28
ID21568A (id) 1999-06-24
EP1312359B1 (en) 2007-08-15
ES2289041T3 (es) 2008-02-01
CA2270952A1 (en) 1998-05-28
IL129824A (en) 2003-07-31
DE69738033D1 (de) 2007-09-27
HUP0000343A2 (hu) 2000-12-28
CN1293876C (zh) 2007-01-10
WO1998022100A3 (en) 1998-06-25
NO992259L (no) 1999-05-10
US20010056124A1 (en) 2001-12-27
CN1237906A (zh) 1999-12-08
CZ174999A3 (cs) 1999-08-11
NZ335629A (en) 2001-09-28
SI1312359T1 (sl) 2008-08-31
BR9713105A (pt) 2000-04-11
ATE275947T1 (de) 2004-10-15
IL129824A0 (en) 2000-02-29
PT941082E (pt) 2004-12-31
EP0941082A2 (en) 1999-09-15
RU2217136C2 (ru) 2003-11-27
CA2270952C (en) 2007-09-18
JP4004070B2 (ja) 2007-11-07
DE69730727D1 (de) 2004-10-21
JP2004256554A (ja) 2004-09-16
GB9624038D0 (en) 1997-01-08
PL333463A1 (en) 1999-12-20
PL190348B1 (pl) 2005-11-30
EP1312359A2 (en) 2003-05-21
US20030069315A1 (en) 2003-04-10
DK1312359T3 (da) 2007-10-08
NO992259D0 (no) 1999-05-10
ES2227726T3 (es) 2005-04-01
HUP0000343A3 (en) 2001-06-28
CN1146411C (zh) 2004-04-21
WO1998022100A2 (en) 1998-05-28
ATE369846T1 (de) 2007-09-15
DE69738033T2 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
HK1022639A1 (en) New use for 1,3-propanediol derivatives.
ZA9110166B (en) 1,4-benzothiazepine derivatives
PT918776E (pt) Sintese total de acilfulvenos antitumorais
ATE172463T1 (de) Pyrrolocarbazol
AU635445B2 (en) New compounds
IL91382A0 (en) Substituted beta-diketones
FI845102L (fi) Imidazo/1,2-c/pyrimidiner.
DE69200862D1 (de) N-2-Chlorbenzyl-2-oxo- und N-2-Chlorbenzyl-2,2,-dioxo-1,2,3-Oxathiazolidinderivate, ihre Herstellung und ihre Verwendung in der Synthese von Thieno[3,2-c]pyridinderivaten.
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081117